USPH Share Price | U.S. Physical Therapy, Inc. Stock Analysis & Recommendation

Q: What does U.S. Physical Therapy, Inc. do?

Overview:U.S. Physical Therapy, Inc. operates outpatient physical therapy clinics providing various rehabilitation services and belongs to the Pharmaceuticals & Biotechnology industry with a small-cap market capitalization.Financial Snapshot:Most recent Net Sales: 184 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 13 Million (Quarterly Results - Mar 2025) Market-cap: USD 1,295.91 Million (Small Cap)Key Metrics:P/E: 28.00 Dividend Yield: 205.86% Debt Equity: 0.34 Return on Equity: 9.58% Price to Book: 2.61 Contact Details:Address: 1300 W Sam Houston Pkwy N Ste 300, HOUSTON TX: 77043-4011 Tel: 1 713 2977000 Website: https://www.usph.com/

Q: Is U.S. Physical Therapy, Inc. overvalued or undervalued?

As of 24 October 2025, the valuation grade for U.S. Physical Therapy, Inc. has moved from fair to expensive, indicating that the stock is overvalued. The company exhibits a P/E ratio of 28, a Price to Book Value of 2.70, and an EV to EBITDA of 17.32, all of which suggest a premium valuation compared to its peers. Notably, The Ensign Group, Inc. has a higher P/E of 32.46, while Option Care Health, Inc. is more attractively valued with a P/E of 23.61.In terms of performance, U.S. Physical Therapy has underperformed against the S&P 500 over the longer term, with a 3-year return of 14.50% compared to the S&P 500's 78.85%. This underperformance, along with the high valuation ratios, reinforces the conclusion that the stock is overvalued.

Q: Is U.S. Physical Therapy, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for U.S. Physical Therapy, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands indicate a bullish stance for both weekly and monthly periods. However, the weekly KST is bullish, but the monthly KST is bearish, and Dow Theory shows a mildly bearish trend on the weekly timeframe. The daily moving averages are bullish. In terms of performance, the stock has underperformed compared to the S&P 500 across multiple periods, with a YTD return of -1.88% versus 16.30% for the S&P 500, and a 5-year return of -1.71% compared to 109.18% for the index. Overall, the current stance is mildly bullish, but the strength is tempered by mixed signals and underperformance relative to the benchmark.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

105.61 k

Shareholding (Dec 2025)

FII

9.46%

Held by 90 FIIs

DII

39.46%

Held by 55 DIIs

Promoter

0.07%

How big is U.S. Physical Therapy, Inc.?

22-Jun-2025

As of Jun 18, U.S. Physical Therapy, Inc. has a market capitalization of $1.30 billion, with net sales of $699.46 million and a net profit of $47.62 million over the latest four quarters.

View full answer

What does U.S. Physical Therapy, Inc. do?

22-Jun-2025

U.S. Physical Therapy, Inc. operates outpatient physical therapy clinics and reported net sales of $184 million and a net profit of $13 million for Q1 2025. The company has a market capitalization of approximately $1.3 billion and key financial metrics include a P/E ratio of 28.00 and a dividend yield of 205.86%.

View full answer

Who are in the management team of U.S. Physical Therapy, Inc.?

22-Jun-2025

As of March 2022, the management team of U.S. Physical Therapy, Inc. includes Edward Kuntz (Independent Chairman), Christopher Reading (President and CEO), Reginald Swanson, Mark Brookner, Harry Chapman, Kathleen Gilmartin, and Bernard Harris (all Independent Directors). They oversee the company's operations and strategic direction.

View full answer

Is U.S. Physical Therapy, Inc. overvalued or undervalued?

28-Oct-2025

As of October 24, 2025, U.S. Physical Therapy, Inc. is considered overvalued with a P/E ratio of 28 and has underperformed the S&P 500, achieving a 3-year return of 14.50% compared to the index's 78.85%.

View full answer

Is U.S. Physical Therapy, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, U.S. Physical Therapy, Inc. shows a mildly bullish trend with mixed technical indicators and has underperformed the S&P 500, yielding a YTD return of -1.88% compared to 16.30% for the index.

View full answer

Compare U.S. Physical Therapy, Inc. with Similar Stocks

NeoGenomics, Inc.RadNet, Inc.Lifestance Health Group, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Management Efficiency with a high ROE of 16.16%

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.36 times

Poor long term growth as Net Sales has grown by an annual rate of 10.85% and Operating profit at 7.40% over the last 5 years

The company has declared Positive results for the last 4 consecutive quarters

With ROE of 9.58%, it has a expensive valuation with a 2.70 Price to Book Value

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,352 Million (Small Cap)

P/E

24.00

Industry P/E

Dividend Yield

200.65%

Debt Equity

0.34

Return on Equity

11.02%

Price to Book

2.68

Revenue and Profits:

Net Sales:

203 Million

(Quarterly Results - Dec 2025)

Net Profit:

13 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-6.58%

6 Months

-9.16%

1 Year

2.33%

2 Years

-31.9%

3 Years

-19.82%

4 Years

-20.79%

5 Years

-30.44%

U.S. Physical Therapy, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

12.15%

EBIT Growth (5y)

7.44%

EBIT to Interest (avg)

25.07

Debt to EBITDA (avg)

1.36

Net Debt to Equity (avg)

0.34

Sales to Capital Employed (avg)

0.96

Tax Ratio

24.42%

Dividend Payout Ratio

95.62%

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

14.64%

ROE (avg)

16.16%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.68

EV to EBIT

19.90

EV to EBITDA

15.24

EV to Capital Employed

2.26

EV to Sales

2.01

PEG Ratio

Dividend Yield

200.65%

ROCE (Latest)

11.34%

ROE (Latest)

11.02%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 65 Schemes (50.94%)

Foreign Institutions

Held by 90 Foreign Institutions (9.46%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 12.36% vs 16.54% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.77% vs 1,344.44% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "202.70",
          "val2": "180.40",
          "chgp": "12.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "27.00",
          "val2": "22.60",
          "chgp": "19.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.40",
          "val2": "2.00",
          "chgp": "20.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-5.50",
          "val2": "2.70",
          "chgp": "-303.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "13.10",
          "val2": "13.00",
          "chgp": "0.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "110.40%",
          "val2": "94.00%",
          "chgp": "1.64%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 16.34% vs 11.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 37.53% vs 15.23% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "781.00",
          "val2": "671.30",
          "chgp": "16.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "104.30",
          "val2": "84.30",
          "chgp": "23.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "9.50",
          "val2": "8.00",
          "chgp": "18.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "3.40",
          "val2": "-2.70",
          "chgp": "225.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "64.50",
          "val2": "46.90",
          "chgp": "37.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "104.90%",
          "val2": "97.80%",
          "chgp": "0.71%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

202.70

180.40

12.36%

Operating Profit (PBDIT) excl Other Income

27.00

22.60

19.47%

Interest

2.40

2.00

20.00%

Exceptional Items

-5.50

2.70

-303.70%

Consolidate Net Profit

13.10

13.00

0.77%

Operating Profit Margin (Excl OI)

110.40%

94.00%

1.64%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 12.36% vs 16.54% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 0.77% vs 1,344.44% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

781.00

671.30

16.34%

Operating Profit (PBDIT) excl Other Income

104.30

84.30

23.72%

Interest

9.50

8.00

18.75%

Exceptional Items

3.40

-2.70

225.93%

Consolidate Net Profit

64.50

46.90

37.53%

Operating Profit Margin (Excl OI)

104.90%

97.80%

0.71%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 16.34% vs 11.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 37.53% vs 15.23% in Dec 2024

All Annual Results

Company CV

About U.S. Physical Therapy, Inc.

U.S. Physical Therapy, Inc.

Pharmaceuticals & Biotechnology

U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care, and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers and neurological-related injuries. The Company's segment is made up of various clinics within partnerships. The Company primarily operates through subsidiary clinic partnerships, in which it owns a general partnership interest and a limited partnership interest, and the managing therapists of the clinics owns the remaining limited partnership interest in the clinics. The Company operates approximately 550 physical therapy clinics in 39 states. In addition to owning and operating clinics, the Company manages approximately 38 physical therapy facilities for unaffiliated third parties, including hospitals and physician groups.

Company Coordinates

Company Details

1300 W Sam Houston Pkwy N Ste 300 , HOUSTON TX : 77043-4011

Tel: 1 713 2977000

https://www.usph.com/

Registrar Details